Type 2 Diabetes Mellitus: Update Bulletin #1

  • ID: 4521382
  • Newsletter
  • FirstWord Publishing
1 of 2

Gain new key opinion leader (KOL) insights on the latest events happening in T2DM. Topics covered include; expert views on Novo Nordisk’s recently approved once-weekly GLP-1 agonist, semaglutide (Ozempic); opinions on the results of the Phase IIIb/IV EXSCEL study which is assessing the cardiovascular (CV) risk of AstraZeneca’s Bydureon (exenatide extended release) in T2DM patients; and views on Zafgen’s ZGN-1061, a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor, which recently entered Phase II clinical development.

Business Questions:
  • Do KOLs perceive semaglutide to have any advantages over other once-weekly GLP-1 agonists?
  • What is KOL perception of semaglutide’s safety profile?
  • Where do experts see this semaglutide fitting into the treatment algorithm?
  • How do KOLs view the results of the EXSCEL study and will it impact prescribing of Bydureon?
  • Do KOLs raise any new safety concerns based on the findings of the EXSCEL study?
  • What strategies do experts suggest for growing Bydureon’s market share?
  • How do KOLs perceive ZGN-1061’s mechanism of action?
  • How do KOLs view ZGN-1061’s subcutaneous mode of delivery?
  • Where do KOLs see ZGN-1061 fitting into the T2DM treatment algorithm?
Note: Product cover images may vary from those shown
2 of 2


3 of 2
Note: Product cover images may vary from those shown